Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study

BACKGROUND: Intermittent treatment with TKIs is an option for the great majority (70%–80%) of CML patients who do not achieve a stable deep molecular response and are not eligible for treatment discontinuation. For these patients, the only alternative is to assume TKI continuously, lifelong. METHODS...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Med
Main Authors: Malagola, Michele, Iurlo, Alessandra, Abruzzese, Elisabetta, Bonifacio, Massimiliano, Stagno, Fabio, Binotto, Gianni, D’Adda, Mariella, Lunghi, Monia, Crugnola, Monica, Ferrari, Maria Luisa, Lunghi, Francesca, Castagnetti, Fausto, Rosti, Gianantonio, Lemoli, Roberto M., Sancetta, Rosaria, Coppi, Maria Rosaria, Corsetti, Maria Teresa, Rege Cambrin, Giovanna, Romano, Atelda, Tiribelli, Mario, Russo Rossi, Antonella, Russo, Sabina, Aprile, Lara, Bocchia, Monica, Gandolfi, Lisa, Farina, Mirko, Bernardi, Simona, Polverelli, Nicola, Roccaro, Aldo M., De Vivo, Antonio, Baccarani, Michele, Russo, Domenico
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2021
主題:
Clinical Cancer Research
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7940223/
https://ncbi.nlm.nih.gov/pubmed/33594821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3778
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍